Company / PP&E (Net)
Moleculin Biotech, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$78.0K
FY2025
5-year range
$78.0K / $338.0K
FY2021-FY2025
Trend
-50.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 5 consecutive years, from $483,000 in FY2020 to $78,000 in FY2025.
Based on SEC 10-K filings.
$78,000 in FY2025 with a 5-year CAGR of -30.6%.
Declined from $272,000 to $78,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -34.3%
- 5-Year CAGR
- -30.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- Moleculin Biotech, Inc.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -30.6%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 50.9% year-over-year.
- Peak pp&e (net) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $78.0K | -50.9% |
| FY2024 | $159.0K | -41.5% |
| FY2023 | $272.0K | -1.1% |
| FY2022 | $275.0K | -18.6% |
| FY2021 | $338.0K | -30.0% |
| FY2020 | $483.0K | +52.8% |
| FY2019 | $316.0K | -31.7% |
| FY2018 | $463.0K | +1303.0% |
| FY2017 | $33.0K | +42.7% |
| FY2016 | $23.1K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026